Memorandum of Cooperation in research, development and innovation of therapy

This Memorandum of Cooperation (MoC) is made and entered into on this 4th day of April 2019 by and between:

Výzkumný ústav balneologický v.v.i. (En. Balneology Research Institute, public research institution), INo 86652061 with seat located at Mšené-lázně, Prosek 174, 411 19, Czech Republic;

and

SOMAVEDIC Technologies s.r.o. (Ltd company), INo 24689173 with seat located at Smetanova 1246/22, Lovosice 410 02, Czech Republic;

Both parties will cooperate to develop smart therapeutical equipment of Program SOMAVEDIC MEDIC URAN

in the frame of Evidence Based Medicine (EBM) approach

Both parties see the benefits of this project, have a desire to pursue the Project and have determined that each one brings unique expertise and experience necessary to accomplish the objective outlined above. This MoC is terminated as of 30th of June 2020. This may be amended from time to time by mutual agreement of the parties in a written modification signed by both parties.

The parties indicate understanding with this Memorandum of Cooperation by their signatures below.

Ing. František Och, director

Balneology Research Institute, pri

Výzkumný ústav balneologický, v.v.l.

Prosek 174 411 19 Mšené-lázně IČ: 866 52 061

Aranka Vítková, director Smetanova 1246/22

Somavedic Technologies s.r.o. DIČ CZ24689173

1C 24689173 +420 725 387 854. 4. 2019

SOMAVEDIC Technologies Sarcio cz somavedic@somave



BRIEF INTERIM REPORT in research, development and innovation of therapy

This Brief Interim Report presents first results of pre-clinical 12 case studies to measure the effect of Somavedic Medic Uran. The cooperation agreement was closed 4th day of April 2019 by and between:

Výzkumný ústav balneologický v.v.i. (En. Balneology Research Institute, public research institution), INo 86652061 with seat located at Mšené-lázně, Prosek 174, 411 19, Czech Republic;

and

SOMAVEDIC Technologies s.r.o. (Ltd company), INo 24689173 with seat located at Smetanova 1246/22, Lovosice 410 02, Czech Republic;

Partial capacity of VUB is devoted to scientific research for evaluation and integration of complementary and alternative medicine (CAM) into common medical practice Evidence based Medicine (EBM). Both sides suppose: Subtle Positive Energies of Somavedic Medic Uran have Healing Impact and Therapeutic Impact. These impacts could support spa effects for health and wellbeing.

Somavedic Technologies Ltd has developed and manufactured Somavedic Medic Uran (SMU). The SMU is designed as a fixed set of mineral crystals, which are excited by an electromagnetic field. Low-energy radiation is produced which has or may have a positive effect on the human organism, or on the environment in which the organism moves. SMU was tested in several laboratories (Czech Republic, Austria, Germany and Slovenia).

Case study: Twelve cases had an initial examination, a brief anamnesis, and a diagnosis. Twelve cases performed BP and pulse measurements for 30 days. Always in the morning under basal conditions after waking up and in the evening before bed, as a last activity. Each person (case) also recorded an Initial, Weekly, and Final Self-Assessment of Feeling Calm or Stress. During the measurement two cases resigned for personal reasons. Pre-clinical investigation of the effects of Somavedic Medic Uran utilized 10 instruments with the production code S / N 2019033741 - 201903750. The preclinical analysis itself was based on data measured by the VEROVAL® wrist tonometer type BPM25. Manufacturer HARTMANN-RICO, Federal Republic of Germany. Measurement method: oscillometric method. Measuring range: systole 50 - 280 mmHg, diastole 30 - 200 mmHg, pulse 40 - 199 beats / min, approved and registered as a medical device, computer interface: Veroval®medi.connect software allows reading data from measured value memory via USB cable and graphic display of measured values on a computer.

Preliminary results: In all the remaining ten cases occurred on the third and fourth week improvement when compared to the average data of the first and the second week. Improvements occurred both in the hard data (5 of which reached BP and P normal standard levels) and in the self-assessment.

Preliminary conclusion: The results of case studies are a good basis for continuing research towards clinical evaluation of the effect of SMU as a medical device.

Mšené-lázně, August 2019

František Och, CEO Balneology Research Institute, pri

Výzkumný ústav balneologický, v.v.l.
Prosek 174
411 19 Mšené-lázně
IČ: 866 52 061
DIČ: CZ86652061